Vascepa is a drug used to reduce the risk of cardiovascular events in certain adult patient groups. The drug was approved by the FDA in 2012 and is currently available in the United States [2]. According to the sources provided, there is no clear information on whether Vascepa is available internationally. The first source, Drug Patent Watch, only provides information on the drug's patents and does not mention its availability outside of the United States [1]. The second source, a press announcement by the FDA, also does not provide information on the drug's availability outside of the United States [2]. The third source is a document from Amarin Corporation, the manufacturer of Vascepa, which mentions that the company is working to expand the drug's availability globally, but does not provide specific information on which countries the drug is available in [3].

In conclusion, while there is no clear information on whether Vascepa is available internationally, the manufacturer of the drug is working to expand its availability globally. Patients outside of the United States who are interested in Vascepa should consult with their healthcare provider or contact Amarin Corporation directly for more information on the drug's availability in their country.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/VASCEPA
[2] https://www.fda.gov/news-events/press-announcements/fda-approves-use-drug-reduce-risk-cardiovascular-events-certain-adult-patient-groups
[3] https://amarincorp.gcs-web.com/static-files/c19c5590-bf2f-4d0c-9eb6-df340f97e918